[go: up one dir, main page]

MX2023008589A - Compuestos moduladores de gcn2 y usos de los mismos. - Google Patents

Compuestos moduladores de gcn2 y usos de los mismos.

Info

Publication number
MX2023008589A
MX2023008589A MX2023008589A MX2023008589A MX2023008589A MX 2023008589 A MX2023008589 A MX 2023008589A MX 2023008589 A MX2023008589 A MX 2023008589A MX 2023008589 A MX2023008589 A MX 2023008589A MX 2023008589 A MX2023008589 A MX 2023008589A
Authority
MX
Mexico
Prior art keywords
gcn2
modulating compounds
modulating
compounds
diseases
Prior art date
Application number
MX2023008589A
Other languages
English (en)
Inventor
Savithri Ramurthy
Mark J Mulvihill
Christopher G Thomson
Bradley Sherborne
Benjamin Rahemtulla
Eric P A Talbot
Original Assignee
Hibercell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hibercell Inc filed Critical Hibercell Inc
Publication of MX2023008589A publication Critical patent/MX2023008589A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Liquid Crystal Substances (AREA)
  • Steroid Compounds (AREA)
  • Holo Graphy (AREA)

Abstract

En la presente se proporcionan compuestos, composiciones y métodos útiles para modular la actividad de GCN2 y para tratar condiciones, enfermedades y trastornos relacionados (por ejemplo, cáncer y enfermedades neurodegenerativas).
MX2023008589A 2021-01-22 2022-01-21 Compuestos moduladores de gcn2 y usos de los mismos. MX2023008589A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163140314P 2021-01-22 2021-01-22
PCT/US2022/013383 WO2022159746A1 (en) 2021-01-22 2022-01-21 Gcn2 modulating compounds and uses thereof

Publications (1)

Publication Number Publication Date
MX2023008589A true MX2023008589A (es) 2023-08-09

Family

ID=80446635

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008589A MX2023008589A (es) 2021-01-22 2022-01-21 Compuestos moduladores de gcn2 y usos de los mismos.

Country Status (14)

Country Link
US (1) US20240083897A1 (es)
EP (1) EP4281182A1 (es)
JP (1) JP2024504364A (es)
KR (1) KR20240021143A (es)
CN (1) CN117203206A (es)
AU (1) AU2022210760A1 (es)
BR (1) BR112023014723A2 (es)
CA (1) CA3209124A1 (es)
CO (1) CO2023010940A2 (es)
CR (1) CR20230408A (es)
IL (1) IL304611A (es)
MX (1) MX2023008589A (es)
PE (1) PE20240691A1 (es)
WO (1) WO2022159746A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202008749D0 (en) 2020-06-09 2020-07-22 Ip2Ipo Innovations Ltd Novel compounds
JP2025517949A (ja) * 2022-05-25 2025-06-12 ハイバーセル，インコーポレイテッド 癌の処置のためのｇｃｎ２モジュレーター
WO2024077092A1 (en) * 2022-10-04 2024-04-11 Hibercell, Inc. Gcn2 inhibitor for treating metastases
WO2024155912A1 (en) * 2023-01-20 2024-07-25 Hibercell, Inc. Crystalline forms of 6-(3-((5-chloro-2-methoxypyridine)-3- sulfonamido)-2,6-difluorophenyl)-n-methylimidazo[l,5- ajpyrazine-l-carboxamide and methods for using the same
WO2025122985A1 (en) * 2023-12-08 2025-06-12 Hibercell, Inc. Methods of treating acute myeloid leukemia using combinations of gcn2 modulators, venetoclax, and azacitidine
WO2025137710A1 (en) * 2023-12-22 2025-06-26 Hibercell, Inc. Methods of treating cancer using combinations of gcn2 modulators and belzutifan

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2542105C (en) * 2003-10-08 2011-08-02 Irm Llc Compounds and compositions as protein kinase inhibitors
JP5490137B2 (ja) * 2008-12-19 2014-05-14 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ プロテインキナーゼ阻害薬としての二環式ピラゾール
EP3498693B1 (en) * 2016-08-10 2024-10-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3746075B1 (en) * 2018-01-29 2025-09-03 Merck Patent GmbH Gcn2 inhibitors and uses thereof
WO2020210828A1 (en) * 2019-04-12 2020-10-15 Hibercell, Inc. (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions
AU2021222818A1 (en) * 2020-02-17 2022-09-01 Alesta Therapeutics BV GCN2 modulator compounds

Also Published As

Publication number Publication date
US20240083897A1 (en) 2024-03-14
CN117203206A (zh) 2023-12-08
PE20240691A1 (es) 2024-04-10
KR20240021143A (ko) 2024-02-16
BR112023014723A2 (pt) 2023-10-03
CO2023010940A2 (es) 2023-12-11
JP2024504364A (ja) 2024-01-31
WO2022159746A1 (en) 2022-07-28
AU2022210760A1 (en) 2023-09-07
CA3209124A1 (en) 2022-07-28
CR20230408A (es) 2024-05-07
EP4281182A1 (en) 2023-11-29
IL304611A (en) 2023-09-01

Similar Documents

Publication Publication Date Title
CR20230408A (es) Compuestos moduladores de gcn2 y usos de los mismos
CR20220626A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
WO2020163823A3 (en) Therapeutic agents and methods of treatment
PH12021552759A1 (en) Substituted cycloalkyls as modulators of the integrated stress pathway
EP4353235A3 (en) Nlrp3 modulators
AU2019362061A8 (en) Androgen receptor modulators and methods for their use
MY209609A (en) Immunomodulators, compositions and methods thereof
MX2021013193A (es) Cicloalquilos sustituidos como moduladores de la vía integrada del estrés.
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
MX2023012245A (es) Compuestos, composiciones y metodos para el tratamiento del cancer.
MY207223A (en) Prodrug modulators of the integrated stress pathway
CR20230057A (es) Compuestos tríciclicos de urea como inhibidores de jak2 v617f
NZ757081A (en) Somatostatin modulators and uses thereof
MX2023005928A (es) Moduladores de malt-1.
MY201080A (en) Nlrp3 modulators
PH12022550491A1 (en) Perk inhibiting pyrrolopyrimidine compounds
MX2022000712A (es) Moduladores de nlrp3.
MX2024011254A (es) Moduladores de nlrp3
WO2022175746A8 (en) Tyk2 inhibitors and uses thereof
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
PH12022551052A1 (en) Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
MX2025005941A (es) Moduladores de la actividad tnf-\03b1
MX2023004942A (es) Compuestos biciclicos y usos de los mismos para el tratamiento de enfermedades.
WO2019143883A3 (en) Compositions and methods for the treatment of cancer
WO2025049274A3 (en) Tetracyclic derivatives, compositions and methods thereof